Literature DB >> 3659830

Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark.

O Kronborg1, C Fenger, O Søndergaard, K M Pedersen, J Olsen.   

Abstract

A Danish study allocated at random 30,970 persons to screening with Hemoccult-II and 30,968 as controls in a population of 140,000 between 45 and 74 years old. Persons with known colorectal cancer, adenoma, and distant spread from all types of cancer were excluded. The test was completed in 20,672 persons from August 1985 to September 1986, and 215 (1%) were found to be positive. Colonoscopy in 203 and double-contrast barium enema in 6 detected 37 persons with cancer and 86 with adenomas. Dukes A cancer was detected in 19 in the screening group, in contrast to 2 among controls. Synchronous adenomas were found in 23 with a positive test and 10 controls. Interval cancer was found in nine persons within 1-11 months after a negative test. Eighteen persons got cancer before invitation and six defectors as well. In all, colorectal cancer was detected in 70 persons in the screening group and in 38 controls; the figures for adenomas alone were 103 and 38, respectively. The study is designed to detect a possible reduction in mortality from colorectal cancer of 25% within 5 years after three screenings with intervals of 2 years. The second screening will begin in September 1987. It remains to be shown whether a reduction may be obtained both in mortality and in incidence of colorectal cancer.

Entities:  

Mesh:

Year:  1987        PMID: 3659830     DOI: 10.3109/00365528709011142

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  25 in total

1.  Is there a preference for different ways of performing faecal occult blood tests?

Authors:  J D Kettner; C Whatrup; J E Verne; K Young; C B Williams; J M Northover
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

2.  Detection rate of immunochemical fecal occult blood test for colorectal adenomatous polyps with severe dysplasia.

Authors:  H Nakama; A S Abdul Fattah; B Zhang; N Kamijo; K Fujimori; K Miyata
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Detecting colorectal cancer with a large scale fecal occult blood testing program.

Authors:  D I Gregorio; P Lolachi; H Hansen
Journal:  Public Health Rep       Date:  1992 May-Jun       Impact factor: 2.792

4.  How can doctors diagnose colorectal cancer earlier?

Authors:  I Maclennan; J Hill
Journal:  BMJ       Date:  1993-06-26

Review 5.  Screening of average-risk individuals for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer.

Authors:  S J Winawer; J St John; J Bond; J D Hardcastle; O Kronborg; B Flehinger; D Schottenfeld; N N Blinov
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

6.  Role of upper gastrointestinal investigations in a screening study for colorectal neoplasia.

Authors:  W M Thomas; J D Hardcastle
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

7.  Screening for colorectal cancer: reasons for refusal of faecal occult blood testing in a general practice in England.

Authors:  K A Hynam; A R Hart; S P Gay; A Inglis; A C Wicks; J F Mayberry
Journal:  J Epidemiol Community Health       Date:  1995-02       Impact factor: 3.710

8.  A simple strategy to improve patient adherence to outpatient fecal occult blood testing.

Authors:  J D Freedman; C K Mitchell
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

9.  Haemoccult does not reduce the need for colonoscopy in surveillance after curative resection for colorectal cancer.

Authors:  C Hall; J Griffin; P W Dykes; J A Williams; M R Keighley
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

10.  Feasibility of family based screening for colorectal neoplasia: experience in one general surgical practice.

Authors:  B M Stephenson; V A Murday; P J Finan; P Quirke; M F Dixon; D T Bishop
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.